197 related articles for article (PubMed ID: 11136389)
1. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P
Haemophilia; 2001 Jan; 7(1):99-102. PubMed ID: 11136389
[TBL] [Abstract][Full Text] [Related]
2. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
[TBL] [Abstract][Full Text] [Related]
3. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
5. [Prevention of joint damage in hemophilic children with early prophylaxis].
Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
[TBL] [Abstract][Full Text] [Related]
6. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
7. Results of secondary prophylaxis in children with severe hemophilia.
Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
[TBL] [Abstract][Full Text] [Related]
8. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
9. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
[No Abstract] [Full Text] [Related]
10. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
[TBL] [Abstract][Full Text] [Related]
11. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
Berntorp E
Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
[TBL] [Abstract][Full Text] [Related]
12. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
Nilsson IM; Berntorp E; Löfqvist T; Pettersson H
J Intern Med; 1992 Jul; 232(1):25-32. PubMed ID: 1640190
[TBL] [Abstract][Full Text] [Related]
13. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
Fischer K; van der Bom JG; Molho P; Negrier C; Mauser-Bunschoten EP; Roosendaal G; De Kleijn P; Grobbee DE; van den Berg HM
Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642
[TBL] [Abstract][Full Text] [Related]
15. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis for severe haemophilia: clinical and economical issues.
Fischer K; Van Den Berg M
Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
[TBL] [Abstract][Full Text] [Related]
17. The overall effectiveness of prophylaxis in severe haemophilia.
Panicker J; Warrier I; Thomas R; Lusher JM
Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
[TBL] [Abstract][Full Text] [Related]
18. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
Fischer K; Astermark J; van der Bom JG; Ljung R; Berntorp E; Grobbee DE; van den Berg HM
Haemophilia; 2002 Nov; 8(6):753-60. PubMed ID: 12410643
[TBL] [Abstract][Full Text] [Related]
20. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
